Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
08:32am, Thursday, 17'th Jul 2025
ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has e
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
12:55pm, Monday, 07'th Jul 2025
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Stereotaxis: Recurring Revenue Inflection
02:13am, Sunday, 06'th Jul 2025
I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo
First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology
09:00am, Tuesday, 01'st Jul 2025
ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publicatio
Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript
07:04pm, Monday, 12'th May 2025
Stereotaxis, Inc. (NYSE:STXS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Partic
Stereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue Estimates
06:20pm, Monday, 12'th May 2025
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago.
Stereotaxis Reports 2025 First Quarter Financial Results
04:01pm, Monday, 12'th May 2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result
Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025
07:00am, Tuesday, 22'nd Apr 2025
ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will
Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025
08:00am, Monday, 21'st Apr 2025
ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
11:10am, Wednesday, 26'th Mar 2025
Investing in surgical robotics stocks like ISRG, ZBH and STXS can be profitable for investors in 2025.
Stereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?
01:05pm, Friday, 21'st Mar 2025
The collaboration, highlighted at NVIDIA's GTC conference, aims to integrate artificial intelligence into surgical robotics, potentially enhancing Stereotaxis' technological capabilities.
Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program
08:01am, Wednesday, 19'th Mar 2025
ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA h
Stereotaxis to Present at 37th Annual Roth Conference
08:02am, Monday, 10'th Mar 2025
ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
01:06pm, Friday, 07'th Mar 2025
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.
Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn
09:10am, Friday, 07'th Mar 2025
I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep
